Generate Biomedicines

Update in progress

GENB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Generate Biomedicines, Inc. operates in generative biology, using machine learning to discover and develop protein therapeutics in the United States. Its programs include GB-0895, a long-acting anti-TSLP monoclonal antibody for severe asthma dosed every six months; GB-4362, an MMAE payload neutralizer; and GB-5267, a MUC16 CAR-T cell therapy. It runs the Generate Platform, a computational-biohardware system for broader modalities. Formerly Generate Biologics, renamed in 2020. Founded 2018, based in Somerville, MA.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive